Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JANX007 + JANX013 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JANX007 | JANX-007|JANX 007 | JANX007 is a trispecific tumor-associated T-cell engager containing binding domains for PSMA, CD3, and albumin, as well as a CD3 inhibitory peptide mask, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). | ||
| JANX013 | JANX-013|JANX 013 | Limited information is currently available on JANX013, a putative immune modulator targeting FOLH1 (PSMA) (Sep 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07813637 | Phase I | JANX007 + JANX013 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC (PSMA-013-001) | Recruiting | USA | 0 |